[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433208":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":123,"collaborators":23,"id":125,"slug":23,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":23,"eligibilityCriteria":130,"healthyVolunteers":126,"sex":131,"minAge":132,"maxAge":23,"enrollmentInfo":133,"targetDuration":23,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":87,"whyStopped":23,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Omission of endocrine therapy","EXPERIMENTAL",[12],"Other: No endocrine therapy",{"label":14,"type":15,"description":14,"interventionNames":16},"Administration of endocrine therapy for at least 5 years","ACTIVE_COMPARATOR",[17],"Other: Endocrine therapy",[19,24],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"No endocrine therapy","No endocrine therapy given",[9],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Endocrine therapy","Endocrine therapy given for at least 5 years",[14],[29],{"name":30,"affiliation":5,"role":31},"Marie-France Savard, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},"Lisa Vandermeer, MSc","CONTACT","613-737-7700","lvandermeer@ohri.ca",{"name":39,"role":35,"phone":36,"phoneExt":23,"email":40},"Marta Sienkiewicz, MSc","msienkiewicz@ohri.ca",[42,56,67,76,85,95,104,114],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":23},"Cross Cancer Institute","NOT_YET_RECRUITING","Edmonton","Alberta","T6G 1Z2","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-113.46871,53.55014,{"lat":54,"lon":53},{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":66,"contacts":23},"Waterloo Regional Health Network","ACTIVE_NOT_RECRUITING","Kitchener","Ontario","N2G 1G3",{"type":51,"coordinates":63},[64,65],-80.5112,43.42537,{"lat":65,"lon":64},{"facility":68,"status":58,"city":69,"state":60,"zip":70,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":75,"contacts":23},"London Health Sciences Centre","London","N6C 2R5",{"type":51,"coordinates":72},[73,74],-81.23304,42.98339,{"lat":74,"lon":73},{"facility":77,"status":58,"city":78,"state":60,"zip":79,"country":48,"countryCode":49,"cosmosGeoPoint":80,"geoPoint":84,"contacts":23},"Oak Valley Health","Markham","L3P 7P3",{"type":51,"coordinates":81},[82,83],-79.2663,43.86682,{"lat":83,"lon":82},{"facility":86,"status":87,"city":88,"state":60,"zip":89,"country":48,"countryCode":49,"cosmosGeoPoint":90,"geoPoint":94,"contacts":23},"The Ottawa Hospital","RECRUITING","Ottawa","K1H8L6",{"type":51,"coordinates":91},[92,93],-75.69812,45.41117,{"lat":93,"lon":92},{"facility":96,"status":58,"city":97,"state":60,"zip":98,"country":48,"countryCode":49,"cosmosGeoPoint":99,"geoPoint":103,"contacts":23},"Thunder Bay Regional Health Sciences Centre","Thunder Bay","P7B 6V4",{"type":51,"coordinates":100},[101,102],-89.25018,48.38202,{"lat":102,"lon":101},{"facility":105,"status":58,"city":106,"state":107,"zip":108,"country":48,"countryCode":49,"cosmosGeoPoint":109,"geoPoint":113,"contacts":23},"Allan Blair Cancer Centre","Regina","Saskatchewan","S4T 7T1",{"type":51,"coordinates":110},[111,112],-104.6178,50.45008,{"lat":112,"lon":111},{"facility":115,"status":58,"city":116,"state":107,"zip":117,"country":48,"countryCode":49,"cosmosGeoPoint":118,"geoPoint":122,"contacts":23},"Saskatoon Cancer Centre","Saskatoon","S7N 4H4",{"type":51,"coordinates":119},[120,121],-106.66892,52.13238,{"lat":121,"lon":120},{"type":124,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100433208",false,"NCT04921137","Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer","A Randomised, Multicentre Trial Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer (REaCT-70)","Inclusion Criteria:\n\n* New invasive estrogen and\u002For progesterone receptor-positive (ER+ and\u002For PR+), HER2-negative (HER2-) invasive breast carcinoma diagnosis as per ASCO-CAP guidelines\n* The primary tumour characteristics are either: Grade 1 and ≤3 cm on microscope exam, OR Grade 2 and ≤2 cm on microscope exam, OR Grade 3 and ≤1 cm on microscope exam\n* Treated with standard loco-regional therapy: breast conserving surgery followed by adjuvant radiotherapy OR total mastectomy\n* Axillary node-negative (cN0 or pN0)\n* Able to provide oral consent and complete questionnaires in French or English as per study protocol\n\nExclusion Criteria:\n\n* Metastatic cancer","ALL","70 Years",{"count":134,"type":135},500,"ESTIMATED","INTERVENTIONAL",[138],"PHASE4","The current standard of care for stage 1 hormone receptor-positive (HR+) breast cancer consists of breast-conserving surgery followed by adjuvant radiotherapy (RT) and endocrine therapy (ET) for at least 5 years. The benefit of adjuvant ET for older patients is mitigated because of their increase risk of death from other causes and shorter time horizon to live. Clinical and pathological factors such as low-intermediate grade, tumor size ≤2 cm, and older age have been used in a few studies to identify patients with a lower risk of recurrence that might benefit from adjuvant therapy de-escalation, i.e. omission of RT or ET. Since there is no dedicated randomized clinical trial (RCT) conducted to evaluate the omission of ET, there is clinical equipoise as to whether we can omit adjuvant ET in older patients with lower-risk early-stage breast cancer. Therefore, we propose a randomised, multicentre trial evaluating harms and benefits of endocrine therapy in patients ≥70 years of age with lower risk breast cancer.",[141],"Breast Cancer",[143,25,144,145],"Radiation therapy","Older patients","Adjuvant therapy","2026-05-25",{"date":148,"type":149},"2026-05-28","ACTUAL",{"date":151,"type":149},"2021-08-19",{"date":153,"type":135},"2036-05",{"name":5,"class":6},8]